CD27: CD27 antigen
Costimulatory immune-checkpoint receptor expressed at the surface of T-cells, NK-cells and B-cells which binds to and is activated by its ligand CD70/CD27L expressed by B-cells.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on CD27, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Varlilumab | Phase 2 | Celldex Therapeutics | Antibody | AgonistCD27 antigen agonist | 3 |
| Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer | Varlilumab | Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | Jun 28, 2021 |
| DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab | Varlilumab | Phase 2 | Active, not recruiting | Annick Desjardins, MD | Sep 28, 2018 |
| Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas | Varlilumab | Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | Feb 1, 2017 |
- Lymphoproliferative syndrome 20.70
- Autosomal recessive lymphoproliferative disease0.66
- Lymphoproliferative syndrome0.62
- Combined immunodeficiency0.57
- Severe combined immunodeficiency0.46
- Immunodeficiency disease0.43
- Neurodegenerative disease0.38
- Hereditary disease0.19
- Autoinflammatory syndrome0.17
- Neoplasm0.12
- Melanoma0.12
- Rheumatoid arthritis0.12
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3713333, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P26842, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets